ADCT
ADC TherapeuticsCNYSE / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
Positive program data and concrete regulatory pathway decisions enable re-rating toward the high end of published targets (~$10.50). Preservation of runway and credible commercialization planning would support execution risk premium compression.
Posture
Mixed
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta 0.0.
What can break
Failure to execute commercialization strategy
Momentum
9
Value
41
Sentiment
100
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $7.50 · Bull $10.50 · Bear $3.50
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-05-29 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-03-11 • Model: RankAlpha Sentiment AI
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $7.80
Why
Momentum9 · Δ7d -4.0
Value41 · Δ7d +0.1
Sentiment100 · Δ7d 0.0
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Lead driver: Sentiment · See AI snapshot
Momentum
9
34% active weight
Current posture
7d trendSoftening
Δ7d
-4.0
Δ21d
-15.5
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
100
33% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
0.0
Why this grade
Composite grade C. Momentum 8.8 / Value 41.1 / Sentiment 100.0
Fundamentals (TTM)As of 2026-05-29
Fundamentals (TTM)
As of 2026-05-29
Market Cap
$432.45M
Beta
1.94
Shares Out
123.88M
P/E (TTM) · Derived
-2.2
P/S (TTM)
5.86
P/FCF (TTM) · Derived
-2.90
Rev YoY
-11.0%
EPS YoY
+13.3%
Gross Margin
+92.7%
Op Margin
-180.9%
Net Debt
$182.86M
Current Ratio
4.63
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology